Phase 1/2a Safety and Immunogenicity of an Adenovirus 26 Vector Respiratory Syncytial Virus (RSV) Vaccine Encoding Prefusion F in Adults 18–50 Years and RSV-Seropositive Children 12–24 Months - Concepedia

Concepedia

Publication | Open Access

Phase 1/2a Safety and Immunogenicity of an Adenovirus 26 Vector Respiratory Syncytial Virus (RSV) Vaccine Encoding Prefusion F in Adults 18–50 Years and RSV-Seropositive Children 12–24 Months

DOI Full Paper Access

37

Citations

19

References

2022

Year

Arabella Stuart, Miia Virta, Kristi L. Williams, Ilkka Seppä, Robyn Hartvickson, Melanie Greenland, Edmund Omoruyi, Arangassery Rosemary Bastian, Wouter Haazen, Nadine C. Salisch,

The Journal of Infectious Diseases

Abstract

Ad26.RSV.preF demonstrated immunogenicity in healthy adults and toddlers, with no safety concerns raised. Evaluations in RSV-seronegative children are underway.

References

	Year	Citations

Page 1